HR
ALXN

Howe & Rusling’s Alexion Pharmaceuticals ALXN Stock Holding History

Howe & Rusling’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40
Closed -$7K – 1058
2021
Q2 		$7K Hold
40
– – ﹤0.01% 554
2021
Q1 		$6K Buy
40
+9
+29% +$1.39K ﹤0.01% 597
2020
Q4 		$5K Sell
31
-4
-11% -$514 ﹤0.01% 643
2020
Q3 		$4K Hold
35
– – ﹤0.01% 624
2020
Q2 		$4K Hold
35
– – ﹤0.01% 589
2020
Q1 		$3K Hold
35
– – ﹤0.01% 606
2019
Q4 		$4K Hold
35
– – ﹤0.01% 603
2019
Q3 		$3K Hold
35
– – ﹤0.01% 658
2019
Q2 		$5K Sell
35
-9
-20% -$1.16K ﹤0.01% 551
2019
Q1 		$6K Buy
44
+2
+5% +$249 ﹤0.01% 525
2018
Q4 		$4K Sell
42
-12
-22% -$1.42K ﹤0.01% 594
2018
Q3 		$8K Hold
54
– – ﹤0.01% 554
2018
Q2 		$7K Hold
54
– – ﹤0.01% 515
2018
Q1 		$6K Sell
54
-10
-16% -$1.2K ﹤0.01% 592
2017
Q4 		$8K Buy
64
+9
+16% +$1.1K ﹤0.01% 502
2017
Q3 		$8K Hold
55
– – ﹤0.01% 525
2017
Q2 		$7K Hold
55
– – ﹤0.01% 567
2017
Q1 		$7K Buy
55
+13
+31% +$1.68K ﹤0.01% 607
2016
Q4 		$5K Buy
+42
New +$5.14K ﹤0.01% 698
2016
Q2 		– Sell
-5
Closed -$1K – 1076
2016
Q1 		$1K Hold
5
– – ﹤0.01% 972
2015
Q4 		$1K Hold
5
– – ﹤0.01% 956
2015
Q3 		$1K Hold
5
– – ﹤0.01% 978
2015
Q2 		$1K Buy
+5
New +$863 ﹤0.01% 1001

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Howe & Rusling's ALXN Position: Q3 2021 in Review

Howe & Rusling sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 40 shares — an estimated $7K sold.

Howe & Rusling first reported a position in ALXN in Q2 2015 and held it in 23 quarters. The position peaked at $8K in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Howe & Rusling reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Howe & Rusling sold 40 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7K.
  • Howe & Rusling first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 23 quarters.
  • Howe & Rusling's Alexion Pharmaceuticals position peaked at $8K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Howe & Rusling's 13F filing for Q3 2021, filed 15 Nov 2021.